Large‐scale genomic sequencing reveals adaptive opportunity of targeting mutated‐PI3Kα in early and advanced HER2‐positive breast cancer
Abstract Background Few studies have discussed the contradictory roles of mutated‐PI3Kα in HER2‐positive (HER2+) breast cancer. Thus, we characterised the adaptive roles of PI3Kα mutations among HER2+ tumour progression. Methods We conducted prospective clinical sequencing of 1923 Chinese breast can...
Guardado en:
Autores principales: | Lin‐Wei Guo, Xiao‐Guang Li, Yun‐Song Yang, Xun‐Xi Lu, Xiang‐Chen Han, Guan‐Tian Lang, Li Chen, Zhi‐Ming Shao, Xin Hu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/95e5f690bc48412b8e7f6cd96e0d6269 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling
por: Ilana Schlam, et al.
Publicado: (2021) -
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
por: Editorial Board
Publicado: (2021) -
Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
por: Serafin Morales, et al.
Publicado: (2021) -
HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods
por: Saglican,Yesim, et al.
Publicado: (2015) -
Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198
por: Jin-xiu Zhong, et al.
Publicado: (2021)